FY2019 EPS Estimates for Lexicon Pharmaceuticals Inc. (LXRX) Lifted by Analyst
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) – Investment analysts at Gabelli raised their FY2019 EPS estimates for Lexicon Pharmaceuticals in a report issued on Friday. Gabelli analyst K. Kedra now forecasts that the firm will post earnings per share of $0.70 for the year, up from their prior estimate of $0.55.
Several other research analysts have also issued reports on LXRX. Needham & Company LLC reiterated a “buy” rating and issued a $21.00 price target on shares of Lexicon Pharmaceuticals in a report on Monday, September 12th. Wedbush reiterated an “outperform” rating and issued a $28.00 price target (down previously from $30.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, May 24th. Zacks Investment Research lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 11th. Citigroup Inc. increased their price target on Lexicon Pharmaceuticals from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, September 12th. Finally, Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, September 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $20.93.
Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at 18.90 on Monday. Lexicon Pharmaceuticals has a 12-month low of $7.65 and a 12-month high of $19.19. The company’s 50 day moving average price is $15.69 and its 200-day moving average price is $13.90. The firm’s market capitalization is $1.96 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/fy2019-eps-estimates-for-lexicon-pharmaceuticals-inc-lxrx-lifted-by-analyst.html
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.04. The business had revenue of $20.10 million for the quarter, compared to analyst estimates of $12.36 million. Lexicon Pharmaceuticals had a negative return on equity of 9.03% and a negative net margin of 13.42%. The firm’s revenue was up 5186.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.27) EPS.
Several hedge funds have recently modified their holdings of LXRX. Acadian Asset Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the second quarter worth approximately $863,000. Eagle Asset Management Inc. increased its stake in shares of Lexicon Pharmaceuticals by 13.3% in the second quarter. Eagle Asset Management Inc. now owns 1,678,732 shares of the biopharmaceutical company’s stock worth $24,089,000 after buying an additional 196,759 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Lexicon Pharmaceuticals during the second quarter worth approximately $274,000. Royal Bank of Canada increased its stake in shares of Lexicon Pharmaceuticals by 4,805.5% in the first quarter. Royal Bank of Canada now owns 31,886 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 31,236 shares during the last quarter. Finally, Bridger Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the first quarter worth approximately $12,308,000.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.